Medi-507 is a humanized monoclonal antibody that binds to the CD2 receptor and suppresses the function of T cells and natural killer cells. The firm is also recruiting patients for a European Phase II study and plans to begin two more Phase II trials later this year. Lori Weiman, dir. Cypress also intends to gain access to other candidates and products for treating fibromyalgia through additional collaborations. Jay Kranzler, CEO, Cypress.
Site licenses are available.